US 100% Tariff on Branded, Patented Drugs Takes Effect 1 October — Indian Generics Stay Exempt, For Now

The United States has brought into effect, from 1 October 2026, a 100% tariff on imports of branded and patented pharmaceutical products, part of its Section 232 action on pharmaceuticals. The headline rate is steep, but for India — the world's largest supplier of generic medicines — the detail that matters most is a carve-out: generic drugs and biosimilars are currently exempt. That exemption shields the bulk of India's roughly US$9–10 billion of pharmaceutical exports to the US. The relief, however, comes with a warning label. The measure contemplates a review within about a year, so the exemption Indian exporters are relying on today is not guaranteed to survive.

This is a corridor read for India-to-USA pharmaceutical exporters: what the measure does, why it largely spares India for now, and how to plan around a carve-out that could change.

What Happened

The US action layers a differentiated tariff structure onto pharmaceutical imports:

• Patented/branded drugs face a 100% tariff as the baseline, with lower negotiated rates for certain trading partners (reported at around 15% for the EU, Japan and South Korea, and a preferential rate for the UK).
• Carve-outs for onshoring. Companies committing to make their products in the US — and, in some framings, to most-favoured-nation pricing — can secure sharply reduced or zero tariffs, with a reduced rate reported for firms committing to domestic manufacturing.
• Generics and biosimilars exempt. Generic medicines, biosimilars and related inputs are, as things stand, outside the 100% tariff.

Because India's US pharmaceutical business is overwhelmingly generics, the immediate direct hit is limited — which is why Indian industry commentators have described the near-term impact as modest.

Why / Background

The logic of the measure is to pressure branded, patent-holding manufacturers to move production into the US, while avoiding a shock to the affordable-medicines supply that American patients depend on. Generics are where that affordability lives, and they are India's strength. The exemption therefore reflects both the structure of US demand and the reality that taxing generics at 100% would raise US drug costs rather than reshore much production. For Indian exporters the result is a reprieve rather than immunity: the policy explicitly leaves the door open to revisiting the scope.

Who's Affected

The firms most exposed are branded or patented-product exporters, including Indian companies shipping innovator or specialty products, and any consignments that could be reclassified out of the "generic" box. The large base of Indian generic and biosimilar exporters is, for now, protected — but should treat that status as provisional. Downstream, US importers, distributors and formulary managers face cost and sourcing questions on the branded side, and contract manufacturers weighing US investment now have a clearer incentive to do so.

What Pharma Exporters Should Do Now

• Confirm, product by product and HS line by HS line, whether each item you ship is treated as generic/biosimilar (exempt) or branded/patented (exposed) under the US measure — the classification, not the molecule, drives the tariff.
• Review contracts with US buyers for who bears tariff cost, and whether Incoterms and pricing clauses pass a 100% duty to the importer or back to you.
• Stress-test your US revenue for the scenario where the one-year review narrows the generic exemption, and identify which products would be hit first.
• If you supply or aspire to supply branded/specialty products, model the economics of US-based manufacturing or partnering against the carve-out terms.
• Keep documentation on product status, approvals and origin clean and ready, in case US customs scrutiny of "generic" claims increases.
• Track the review timeline and any implementing proclamations rather than assuming today's exemption is permanent.

The Bigger Picture

The measure crystallises a strategic question India's pharma sector has faced for a while: the US generic franchise is large, essential and — for the moment — shielded, but it sits inside a trade relationship where tariff policy has become an active lever. The near-term story is continuity for generics. The medium-term story is risk management: a one-year review clause means the most valuable exemption in the India-to-USA corridor is conditional. Exporters who use this window to diversify markets, firm up contracts and understand their product-classification exposure will be better placed if the scope shifts.

Frequently Asked Questions

Are Indian generic drug exports to the US taxed at 100%? No. As the measure stands from 1 October 2026, generic medicines and biosimilars are exempt. The 100% tariff targets branded and patented products.

Could the exemption be removed? Yes. The action contemplates a review within about a year, which could bring additional categories into scope. Treat the current exemption as provisional.

What rate applies to branded drugs from other countries? Reported rates are lower for some partners (around 15% for the EU, Japan and South Korea, and a preferential rate for the UK), with carve-outs for companies committing to US manufacturing.

Does this change anything for CDSCO or Indian export documentation? The tariff is a US import measure; it does not change Indian regulatory requirements. But accurate product classification and clean approval/origin documentation help defend "generic" status at the US border.

Conclusion

For India-to-USA pharmaceutical exporters, 1 October 2026 is less a cliff than a conditional reprieve. Generics — the heart of the trade — remain exempt, so the immediate disruption is limited. The task now is to confirm product-level classification, tighten who-pays clauses with US buyers, and plan for the possibility that a review narrows the exemption. Certainty here rests on US policy that is still evolving.

This is general analysis based on current reports, not legal or trade advice. US tariff measures are evolving — verify scope, rates and effective dates against official US proclamations and CBP guidance, and consult a trade adviser before acting.